CRVS — Corvus Pharmaceuticals, Inc.

Summary of Corvus Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Financials:
  • Research and Development (R&D) expenses were $9.9 million, up from $6 million in Q4 2024.
  • Full-year R&D expenses totaled $33.7 million, compared to $19.4 million in 2024.
  • Net loss for Q4 2025 was $12.3 million, slightly higher than the $12.1 million loss in Q4 2024.
  • Cash, cash equivalents, and marketable securities as of December 31, 2025, were $56.8 million, up from $52 million in 2024.
  • Following a public offering in January 2026, pro forma cash is approximately $246 million, extending the cash runway into Q2 2028.

2. Strategic Updates and Business Highlights

• Clinical Progress: Significant advancements in the development of soquelitinib, a selective ITK inhibitor, were reported, with promising results from Phase I/Ib trials in peripheral T-cell lymphoma (PTCL) and atopic dermatitis.
• Data Presentation: Final results from the Phase I/Ib trial in PTCL were presented at the ASH Annual Meeting, and data from cohort 4 of the atopic dermatitis trial indicated strong efficacy and durability of response.
• Pipeline Expansion: Plans to initiate Phase II trials for hidradenitis suppurativa and asthma later in 2026, leveraging the drug's novel mechanism of action.
• Investor Interest: A $200 million financing was completed, reflecting strong investor confidence in soquelitinib's potential across multiple indications.

3. Forward Guidance and Outlook

• Upcoming Milestones:
  • Enrollment continues in the Phase III PTCL trial, with an interim analysis expected later in 2026.
  • Results from the Phase II atopic dermatitis trial are anticipated in mid-2027.
  • The company is optimistic about soquelitinib's positioning as a leading therapy for atopic dermatitis and other inflammatory diseases, supported by ongoing clinical data.

4. Bad News, Challenges, or Points of Concern

• Financial Losses: The company continues to report significant net losses, which may raise concerns about sustainability without continued funding or successful product commercialization.
• Regulatory Risks: The ongoing clinical trials are subject to regulatory scrutiny and could face delays or challenges that may impact timelines and financial projections.
• Competitive Landscape: The market for atopic dermatitis and other inflammatory diseases is competitive, with established therapies already available, which could pressure market entry and pricing strategies.

5. Notable Q&A Insights

• Data Readouts: Analysts inquired about the implications of upcoming data from the PTCL and the China study on the Phase II atopic dermatitis trial. Management indicated that the data from Angel Pharmaceuticals would be crucial for understanding efficacy and safety.
• Durability of Response: There was a focus on the durability of soquelitinib's effects, with management asserting that over 90% of patients maintained responses beyond treatment, which could differentiate it from existing therapies.
• Trial Design Considerations: Questions arose regarding the inclusion of patients with prior systemic therapy failures in the atopic dermatitis trial, which management confirmed would be part of their strategy to assess the drug's effectiveness in more challenging patient populations.
• Market Positioning: Management expressed confidence in soquelitinib's potential across multiple indications, emphasizing its unique mechanism of action and safety profile compared to existing treatments.

Overall, Corvus Pharmaceuticals is making significant strides in its clinical development of soquelitinib, with a strong financial position bolstered by recent funding, though challenges remain in the competitive and regulatory landscape.